Bevacizumab(Beijing Science Sun)

The primary study objective was to compare the pharmacokinetic (PK) similarity of the experimental drug humanized anti-VEGF monoclonal antibody injection (specification: 100 mg/4 mL, produced by Beijing Saisheng Pharmaceutical Co., Ltd.) and the control drug bevacizumab injection [Avastin, specification: 100 mg/4 mL, produced by Roche Diagnostics GmbH (European source), provided by Beijing Saisheng Pharmaceutical Co., Ltd.] in healthy Chinese male volunteers after a single intravenous drip of 1 mg/kg. The secondary study objective was to evaluate the safety, tolerability and immunogenicity of humanized anti-VEGF monoclonal antibody injection and bevacizumab injection (Avastin) in healthy Chinese male volunteers after a single intravenous drip.